CurrentAvMedPolicy N/A

IV tocilizumab products - Giant Cell Arteritis (GCA)

Defines prior authorization, step-edit, and clinical criteria for intravenous tocilizumab (Actemra and biosimilars) for treatment of Giant Cell Arteritis for AvMed members; applies to providers prescribing medical-administered tocilizumab.

Policy Summary

PayerAvMed

PolicyIV tocilizumab products - Giant Cell Arteritis (GCA)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization and supporting documentation showing diagnosis verification, prior therapies, and relevant labs or imaging.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12 monthsInitial auth duration

12 monthsReauth duration

6 mg/kg q4wIV dosing

>=18Min age

Coverage Criteria for IV Tocilizumab (GCA)

Initial Authorization — Covered when ALL of the following are met

Covered when ALL of the following are met

Initial Authorization Criteria: Prescribed by or in consultation with a Neurologist, Ophthalmologist, or Rheumatologist; diagnosis of Giant Cell Arteritis (GCA) with large vessel arteritis verified by biopsy or imaging (e.g., color Doppler ultrasound, MRI, PET-CT, or CT angiography); member is at least 18 years of age; member has tried one systemic corticosteroid.

All documentation (labs, diagnostics, chart notes) must be provided. Recommended IV dosing: 6 mg/kg (maximum 600 mg) once every 4 weeks in combination with glucocorticoids.

Reauthorization — Covered when ALL of the following are met

Covered when ALL of the following are met

Reauthorization Criteria: Member has experienced disease response as indicated by improvement in signs and symptoms compared to baseline (for example: headache, temporal artery tenderness, visual symptoms), improvement in inflammatory markers (e.g., ESR, CRP), or improvement on periodic imaging studies (CDUS, MRI, PET-CT, or CT angiography).

Policy Summary

PayerAvMed

PolicyIV tocilizumab products - Giant Cell Arteritis (GCA)

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization and supporting documentation showing diagnosis verification, prior therapies, and relevant labs or imaging.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Documentation including lab results, diagnostics, and chart notes must be provided.

Step Therapy for Non-Preferred Agent

Tofidence (non-preferred) specific: For Tofidence requests, member must have tried and failed BOTH preferred agents Actemra and Tyenne and meet all prior authorization criteria for approval of Tofidence.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.

Use of medication samples to initiate therapy does not meet step edit or prior authorization criteria. Requests that rely on samples in lieu of documented trials of preferred agents will not satisfy step therapy requirements and may be denied or returned for additional documentation.

Billing and Code References

Preferred HCPCSHCPCSCovered

J3262	Actemra IV (tocilizumab)
Q5135	Tyenne IV (tocilizumab-aazg)

Non-Preferred HCPCSHCPCSCovered

Q5133

Tofidence IV (tocilizumab-bavi)

IV dosing (inv-07)

Recommended IV dosing6 mg/kg (maximum 600 mg) once every 4 weeks (in combination with glucocorticoids)

Route and productsIntravenous administration for Actemra and tocilizumab biosimilars

Use with glucocorticoidsAdminister in combination with systemic glucocorticoids per prescribing guidance

Weight-based dosing noteDose calculated by patient weight; maximum single dose 600 mg

Provider Requirements and Prior Authorization

Prior Authorization

Prior Authorization Required

Prior Authorization Required: IV tocilizumab products for Giant Cell Arteritis (GCA) require prior authorization. Authorization may be delayed or denied if the information provided is not complete, correct, or legible. The prescribing physician must sign and clearly print their name on the request (preprinted stamps are not valid).

Fax completed request to 1-877-535-1391
Medicare Part B coverage and any applicable NCDs/LCDs must be followed where relevant

Step Therapy

Step Therapy for Non‑preferred Agent (Tofidence™)

For non-preferred Tofidence™ IV (tocilizumab-bavi, Q5133) requests, the member must have tried and failed BOTH preferred agents (Actemra® IV [J3262] and Tyenne™ IV [Q5135]) and meet all other prior authorization criteria for approval. Document prior trials and failures in the chart notes.

Tofidence™ (Q5133) is non-preferred — prior trials of Actemra® (J3262) and Tyenne™ (Q5135) required
All PA criteria for Tofidence™ must be met in addition to step therapy requirement

Documentation Required

Documentation requirement: Support each checked clinical criterion with documentation including lab results, diagnostics, and chart notes. Prior therapies (e.g., systemic corticosteroid trial and trials of preferred tocilizumab products when applicable) must be documented. Requests lacking supporting documentation may be denied.

Include labs (e.g., ESR, CRP) and imaging or biopsy reports verifying GCA when indicated
Include weight and date weight obtained if dosing is weight-based (6 mg/kg, max 600 mg)
Provide notes showing prescriber specialty (neurologist, ophthalmologist, or rheumatologist) and treatment response for reauthorization

Denial Risk

Provider Signature and Submission

Provider action: The prescribing physician must sign and clearly print their name on the request form (preprinted stamps are not valid). Authorization can be delayed or denied if information provided is not complete, correct, or legible.

Use Standard Review box only when timeframe does not jeopardize life/health or ability to regain maximum function
Fax to 1-877-535-1391

Clinical Background

Giant Cell Arteritis (GCA) with large-vessel involvement is managed with systemic corticosteroids and, when indicated, may be treated with tocilizumab in combination with glucocorticoids. Intravenous tocilizumab dosing for GCA is recommended at 6 mg/kg (maximum 600 mg) once every 4 weeks, and therapy is generally directed by or in consultation with specialists experienced in GCA management (for example, rheumatology, ophthalmology, or neurology).

Definitions

Verified GCA (inv-13)

DefinitionDiagnosis of Giant Cell Arteritis (GCA) with large vessel arteritis verified by biopsy or imaging of large vessels (e.g., color Doppler ultrasound [CDUS], MRI, PET-CT, or CT angiography)

Acceptable imaging modalitiesColor Doppler ultrasound (CDUS), MRI, PET-CT, or CT angiography

Verification timingVerification may have occurred at any point in the patient’s diagnostic course (documented historically or currently)

Age contextApplied in members aged ≥18 years as part of authorization criteria